New research says global prostate cancer drug market will reach $13.6 billion by 2021

12 November 2015

The global treatment market for prostate cancer will expand rapidly from $7.6 billion in 2014 to $13.6 billion by 2021, representing a compound annual growth rate (CAGR) of 9.5%.

According to business intelligence provider GBI Research’s latest report, the rise, which will occur across the eight major markets of the USA, Canada, France, Germany, Italy, Spain, the UK and Japan, will be driven primarily by growth in disease prevalence due to an aging global population.

Katie Noon, senior analyst for GBI Research, says the continued uptake of Zytiga (abiraterone acetate), from Johnson & Johnson (NYSE: JNJ), and Xtandi (enzalutamide), from Medivation (Nasdaq: MDVN) and Japanese partner Astellas Pharma (TSE: 4503), and the approval of several premium products will also be key factors aiding prostate cancer therapy market growth by 2021.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK